- Trials with a EudraCT protocol (1,560)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,560 result(s) found for: radiation therapy.
Displaying page 6 of 78.
EudraCT Number: 2009-012595-27 | Sponsor Protocol Number: A8081007 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (... | |||||||||||||
Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001409-34 | Sponsor Protocol Number: MO39171 | Start Date*: 2017-11-20 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL C... | |||||||||||||
Medical condition: Malignant neoplasm of bronchus and lung (nsc) adv. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) SE (Completed) DK (Completed) LV (Completed) PL (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003127-41 | Sponsor Protocol Number: BT009E | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:INSIGHTEC | |||||||||||||
Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla... | |||||||||||||
Medical condition: Recurrent Glioblastoma (rGBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003203-14 | Sponsor Protocol Number: TUXEDO-2 | Start Date*: 2023-05-02 |
Sponsor Name:Med. Univ. Wien, Klinik f. Innere Medizin I, Onkologie | ||
Full Title: Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases | ||
Medical condition: triple negative breast cancer with newly diagnosed or progressing brain metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004375-11 | Sponsor Protocol Number: AS1404-202 | Start Date*: 2005-03-30 |
Sponsor Name:Antisoma Research Limited | ||
Full Title: AN OPEN LABEL, RANDOMISED, PHASE II STUDY OF AS1404 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN EPITHELIAL CANCER | ||
Medical condition: Platinum Sensitive Recurrent Ovarian Epithelial Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) DE (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000864-42 | Sponsor Protocol Number: IFX-1-P2.8 | Start Date*: 2021-04-27 | |||||||||||
Sponsor Name:InflaRx GmbH | |||||||||||||
Full Title: OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOU... | |||||||||||||
Medical condition: Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004693-27 | Sponsor Protocol Number: A6181064 | Start Date*: 2006-11-09 |
Sponsor Name:Pfizer Ltd. | ||
Full Title: A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS | ||
Medical condition: Advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) AT (Prematurely Ended) SE (Prematurely Ended) FI (Completed) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005020-42 | Sponsor Protocol Number: M11-089 | Start Date*: 2014-05-15 | |||||||||||
Sponsor Name:Abbvie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastati... | |||||||||||||
Medical condition: Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) FI (Completed) LT (Completed) CZ (Completed) PT (Completed) HU (Completed) NO (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) IE (Completed) DK (Completed) NL (Completed) ES (Completed) GR (Completed) LV (Completed) PL (Completed) FR (Completed) HR (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002799-28 | Sponsor Protocol Number: TG4001.12 | Start Date*: 2020-03-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Transgene | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of the he... | ||||||||||||||||||||||||||||||||||||||
Medical condition: HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002941-49 | Sponsor Protocol Number: ERRITI | Start Date*: 2017-01-31 |
Sponsor Name:University Hospital Essen (Anstalt des öffentlichen Rechts) | ||
Full Title: Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study | ||
Medical condition: Radio Iodine Refractory Thyroid Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001108-35 | Sponsor Protocol Number: NRA 6290010 | Start Date*: 2006-07-03 | |||||||||||
Sponsor Name:Clinic of University of Wuerzburg | |||||||||||||
Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY | |||||||||||||
Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001203-36 | Sponsor Protocol Number: CI-IPOP.22-2012 | Start Date*: 2014-02-07 | ||||||||||||||||
Sponsor Name:Instituto Português de Oncologia do Porto Francisco Gentil, EPE | ||||||||||||||||||
Full Title: Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer | ||||||||||||||||||
Medical condition: Rectal cancer stage II Rectal cancer stage III | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002340-42 | Sponsor Protocol Number: SBG-2-03 | Start Date*: 2008-09-16 | |||||||||||
Sponsor Name:Biotec Pharmacon ASA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck can... | |||||||||||||
Medical condition: Oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001065-21 | Sponsor Protocol Number: ET21-023 | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) | |||||||||||||
Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004758-39 | Sponsor Protocol Number: ESR-18-13485 | Start Date*: 2019-06-12 | |||||||||||
Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA | |||||||||||||
Full Title: A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER | |||||||||||||
Medical condition: Locally advanced (T3-4 N0-1) rectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001083-30 | Sponsor Protocol Number: VIGAS2 | Start Date*: 2019-06-02 |
Sponsor Name:Karolinska Institutet | ||
Full Title: A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients | ||
Medical condition: Glioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000721-21 | Sponsor Protocol Number: CA163-140 | Start Date*: 2007-09-24 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer. | |||||||||||||
Medical condition: Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) GR (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000121-19 | Sponsor Protocol Number: CapRI 2 | Start Date*: 2008-08-11 | |||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||
Full Title: A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ... | |||||||||||||
Medical condition: Patients with Resected Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000528-22 | Sponsor Protocol Number: GOIRC01/2008 | Start Date*: 2008-02-21 | ||||||||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA | ||||||||||||||||||
Full Title: Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 ov... | ||||||||||||||||||
Medical condition: Patients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breast | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002370-64 | Sponsor Protocol Number: AUPSG 01/07 | Start Date*: 2007-06-11 | |||||||||||
Sponsor Name:Austrian Prostate Study Group (AUPSG) | |||||||||||||
Full Title: Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer | |||||||||||||
Medical condition: metastatic hormone-refractory prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
